AngioDynamics has announced the appointment of Eric Honroth as president and chief executive officer and a member of the board of directors, effective 2 November 2026. Honroth will succeed Jim Clemmer, who will depart the board on the same date but will remain in a consulting capacity.
The company have shared that the appointment follows a board-led search prioritising a leader with medical technology experience, a demonstrated track record of commercial execution and operational discipline to build on the company’s Med Tech momentum, advance its transformation, and drive sustainable revenue growth, margin expansion, and long-term shareholder value.
In a recent press release, the company shares that Honroth brings more than 20 years of medical device and life sciences leadership experience across markets directly aligned with AngioDynamics’ portfolio, including cardiovascular, endovascular, urology and oncology. Earlier in his career, he held senior leadership roles at Abbott Vascular, Becton Dickinson, CareFusion, and Boston Scientific. His leadership experience spans both North American and global markets, including responsibility for large-scale commercial organisations and global business operations, providing a proven foundation for advancing the Company’s strategic growth and value-creation priorities.
Most recently, he served as global president, Life Science at Getinge and previously led Getinge’s North American business.
“AngioDynamics enters this transition with real momentum, including a high-growth Med Tech segment, a strong balance sheet with no outstanding debt, and an operational transformation that is delivering,” said Howard Donnelly, AngioDynamics board chair. “Eric has done what this moment requires. He has built businesses, driven profitable growth, and managed global operations with responsibility for both revenue and cost structure. He also builds teams and leads with a genuine commitment to patients, and the board is confident he is the right leader to deliver long-term value during our next chapter.”
Donnelly continued, “On behalf of the board, I want to thank Jim for his exceptional leadership over the past decade. Under his guidance, AngioDynamics underwent a successful transformation that sharpened our focus and built a solid foundation for sustainable growth and profitability. Jim’s dedication to our team, patients, customers, and shareholders has left a lasting mark on the Company, and we are deeply grateful for his many contributions. We look forward to his continued contributions as a trusted senior advisor.”
“I am honoured to lead AngioDynamics at such an important moment for the company and grateful for the confidence the board and Jim have placed in me,” said Honroth. “The company has a differentiated technology portfolio, multiple growth drivers, and an exceptionally talented team. I look forward to working with employees and customers to build on this foundation and accelerate progress where we see the greatest opportunities to improve patient care and create shareholder value.”
“It has been the privilege of my career to lead AngioDynamics these past ten years,” said Clemmer. “Together, we sharpened the company’s focus, expanded operating capabilities, and positioned the business for its next phase of growth. I am confident Eric’s experience and leadership make him the right person to carry that work forward, and I look forward to supporting a smooth transition.”
